Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek August 22, 2005 Gene G. Marcial	New River May Have A "Blockbuster" For ADHD New River Pharmaceuticals has yet to make a dime - but investors love it.
The Motley Fool October 30, 2006 Brian Lawler	Building a Future Shire ADHD drugs are big for Shire now, but the long term isn't as clear. Investors, take note.
The Motley Fool February 26, 2007 Brian Lawler	Shire's Busy Week Shire Pharmaceuticals announces year-end results, new regulatory approval, and another acquisition.
The Motley Fool October 9, 2007 Brian Lawler	Shire Slims Down, Slightly The U.K.-based pharmaceutical sells off some of its marketed drugs in order to focus more on its key ADHD franchises.
The Motley Fool October 9, 2006 Brian Lawler	New Drug for New River An approvable letter from the FDA sends shares of New River Pharmaceuticals up.
The Motley Fool July 27, 2007	Shire's Got Focus: Fool by Numbers Revenue and guidance are up at Shire, led by improved sales of their ADHD drugs.
The Motley Fool September 5, 2007 Brian Lawler	Not Your Typical Product Recall Shire and Noven will fix an annoying foible of their ADHD patch, Daytrana, making the back adhesive easier to unpeel.
The Motley Fool August 15, 2006 Stephen D. Simpson	Twirling the Barr Look closely and you'll see that Barr posted a solid quarter. Investors, if you haven't checked this one out yet, now may be the time for a little due diligence.
The Motley Fool August 19, 2004 Charly Travers	1 Pill for Sleep, Attention Ailments? Cephalon gets some good news about its drug PROVIGIL.
The Motley Fool May 25, 2011 David Williamson	Pay Attention to Shire The British ADHD medicine maker is busy making big moves.
The Motley Fool February 7, 2006 Stephen D. Simpson	Barr None Bargain hunters are probably going to come up short when it comes to assessing Barr Pharmaceuticals' stock, but a fairly rich package of opportunities should keep growth strong for the immediate future.
The Motley Fool February 26, 2007	Sales Up at Shire Pharmaceuticals: Fool by Numbers The drugmaker released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool May 12, 2008 Brian Orelli	Lowering the Barr Barr Pharmaceuticals disappoints by lowering expectations.
The Motley Fool April 2, 2007 Brian Lawler	Pain Therapeutics Pares Shares The small drugmaker announces a share buyback.
The Motley Fool June 30, 2008 Brian Orelli	Johnson & Johnson Grows Up a Little Its Concerta for attention-deficit disorder is approved for use in adults.
The Motley Fool May 1, 2007 Brian Lawler	Pay Attention to Noven The drug developer announced results from another quarter of strong growth. Revenue doubled versus the year-ago period as sales of its attention-deficit hyperactivity disorder patch, Daytrana, began to pick up.
The Motley Fool August 20, 2007 Brian Lawler	Are These Perfect Pharma Acquisitions? Weighing recent drug-industry deals' odds of success: AstraZeneca and MedImmune... Shire and New River Pharmaceuticals... Gilead and Myogen...
The Motley Fool July 12, 2007 Brian Lawler	Noven's Novel Acquisition With JDS Pharmaceuticals, the company is moving toward more traditional oral drugs. Investors, take note.
The Motley Fool November 9, 2006 Brian Lawler	Noven Might Be in a Purple Patch Investors in Noven shares might as well pay most of their attention to Shire, because as long as Daytrana does well, so too will Noven.
The Motley Fool July 28, 2009 Brian Orelli	All Growth, All the Time This generic-drug maker is no value play.
The Motley Fool November 8, 2006 Brian Lawler	Barr's Wounded Quarter If your revenues live by the generic sword, they can die by it, too. That seems to be the case today for Barr Pharmaceuticals. Investors, take note.
The Motley Fool December 26, 2006 Brian Lawler	Barely a Ripple for New River With New River's $2 billion market cap, no recurring revenues to speak of, and the terms of its partnership with Shire still uncertain, these shares are more than a tad too rich.
Pharmaceutical Executive June 1, 2012	Raising the Stakes in CNS As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory.
BusinessWeek March 27, 2006 Gene G. Marcial	Cortex Draws A Bead On Hyperactivity When Cortex Pharmaceuticals disclosed on Mar. 8 that its lead drug, CX717, showed favorable results in Phase 2 trials for the treatment of adult ADHD, the stock jumped.
BusinessWeek October 27, 2003 Catherine Arnst	Attention Deficit: Not Just Kid Stuff Drugmakers are starting to target an overlooked group: Adults with ADHD.
American Family Physician May 1, 2001	Learning About ADHD in Children ADHD, or attention-deficit/hyperactivity disorder, is a common health problem in children. Children with ADHD are hyperactive--they can't sit still. They are also impulsive and easily distracted. They have trouble coping at school and at home...
The Motley Fool August 28, 2008 Brian Orelli	Me-Too Drugs: Are They Worth It? These drugs have less risk, but also usually bring less of a reward to the companies that make them.
The Motley Fool November 3, 2010 Brian Orelli	Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits.
The Motley Fool September 8, 2005 Stephen D. Simpson	Raising the Barr This large generics company sees better margins and an optimistic outlook. The company has a top-notch return on assets and a valuation that, while not cheap, isn't ridiculous either.
Chemistry World January 26, 2015 Phillip Broadwith	Shire deepens rare disease focus with NPS buyout UK specialty pharmaceutical firm Shire has agreed to buy US biotech NPS Pharmaceuticals for $5.2 billion.
American Family Physician November 1, 2000	When Adults Have ADHD Attention-deficit/hyperactivity disorder is also called ADHD. People with ADHD are hyperactive or distracted most of the time. Even when they try to concentrate, they find it hard to pay attention...
The Motley Fool October 30, 2007 Brian Orelli	Big Pharma's Takeover Wish List Which companies may be the next big pharma buyout candidates? Investors, take note.
The Motley Fool December 5, 2005 W.D. Crotty	Cashing In on Noven's Drug Patch An FDA advisory panel recommends approval of Noven's patch for attention deficit hyperactivity. For now, investors might be put off by the company's lofty valuation of 55 times trailing earnings.
Chemistry World June 23, 2014 Phillip Broadwith	Shire fends off AbbVie takeover bid Shire is the latest pharmaceutical company to be targeted for a multi-billion dollar takeover deal from a firm looking to transfer its tax residence outside the US.
Pharmaceutical Executive October 1, 2005	Thought Leader: Room for Improvement An interview with Randal J. Kirk, founder of New River Pharmaceuticals, whose drug technology team has made it its goal to introduce safer, more efficacious and reliable models of existing franchise drugs.
The Motley Fool November 12, 2007 Brian Orelli	Raising the Barr Barr Pharmaceuticals' acquisition of Pliva increases sales, but it doesn't help raise the bottom line. Investors, take note.
The Motley Fool July 16, 2007 Brian Orelli	Business as Usual for Barr The maker of generic drugs gets sued twice in one week. Investors appear to be getting used to Barr's method of operation; the news of the lawsuits didn't hurt the stock price.
The Motley Fool July 26, 2007 Brian Orelli	Barr Gets Sued, Again This is starting to be a bad habit at Barr Pharmaceutical. The drug maker has just been sued for the third time in as many weeks. The latest one is by Schering-Plough, over patent infringement of its brain cancer treatment drug.
The Motley Fool May 2, 2007 Mike Havrilla	Consider Cortex New findings may give Cortex's ADHD drug the lift it needs. The news represents an excellent opportunity for speculative biotech investors
Chemistry World November 11, 2013 Phillip Broadwith	Shire will cut UK R&D to focus on rare diseases Shire Pharmaceuticals has begun an employee consultation process as it seeks to discontinue a significant proportion of research and development activities at its historic UK base in Basingstoke.
Chemistry World November 2010	Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream?
The Motley Fool December 17, 2007 Brian Orelli	Barr Labs' Legal Tables Turned Barr Labs announces that is suing both Watson Pharmaceuticals and Novartis' generic subsidiary Sandoz for patent infringement regarding Barr's SEASONALE extended-cycle birth control pill.
The Motley Fool August 7, 2008 Brian Orelli	The Next Pharma Acquisition The rate of mergers and acquisitions among drugmakers has reached a feverish pace lately, and doesn't show any signs of slowing down anytime soon. Take a look at some likely candidates.
The Motley Fool August 29, 2008 Brian Orelli	A Lawsuit Loss to Remember Barr Pharmaceuticals and Mylan get the patent overturned on Johnson & Johnson's Alzheimer's drug.
The Motley Fool February 3, 2010 Brian Orelli	Pfizer's Hedge Pays Off FDA wants more data from Pfizer's partner, Protalix on their treatment for Gaucher disease.
The Motley Fool February 29, 2008 Brian Orelli	Barred by Debt The picture continues to look bleak at Barr Labs, due to debt taken on to acquire Pliva in 2006.
The Motley Fool June 27, 2008 Brian Orelli	Barr's Lawyers Earn Their Keep Generic-drug maker Barr Pharmaceutical gets another patent thrown out.
The Motley Fool August 31, 2011 Brian Orelli	Shire Enters a Crowded Market Last week, the FDA approved Shire Pharmaceuticals' Firazyr to treat a rare genetic disease.
BusinessWeek January 10, 2005 Mara Der Hovanesian	Barr: A No-Name Star More than $30 billion in patents will elapse by the end of 2007, which spells new potential for generics such as Barr Pharmaceuticals. With Barr's solid pipeline, the stock, at $46, is a bargain.
The Motley Fool June 18, 2009 Brian Orelli	Your Stocks Just Got Riskier It's been a busy week for the Food and Drug Administration, and not in the bust-out-the-champagne-we-got-an-approval way. Is the FDA cracking down on pharmaceutical companies?